Adial Pharmaceuticals - Warrants (31/07/2023) Stock News

Geode Capital Management LLC raised its stake in Adial Pharmaceuticals, Inc. by 13.2% during the 2nd quarter, according to the company in its most recent 13F filing with the

Geode Capital Management LLC raised its stake in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) by 13.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 88,246 shares of the companys stock after acquiring an additional 10,261 shares during the quarter. Geode Capital Management [] The post Geode Capital Management LLC Buys 10,261 Shares of Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) appeared first on ETF Daily News .

PNV2 demonstrates reduction of metastases in animal model PNV2 demonstrates reduction of metastases in animal model

CHARLOTTESVILLE, Va., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on de

CHARLOTTESVILLE, Va., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, reminds investors that it will host a conference call at 11:00 A.M. Eastern Time on Thursday, November 18, 2021 to provide a clinical update and discuss the latest business developments.

Adial Pharmaceuticals (NASDAQ:ADIL) released its quarterly earnings results on Sunday. The company reported ($0.22) EPS for the quarter, hitting the Zacks consensus estimate of ($0.22), Fidelity Earnings reports. ADIL traded up $0.03 during trading on Tuesday, hitting $3.19. 195,402 shares of the stock traded hands, compared to its average volume of 702,662. The firm has []

CHARLOTTESVILLE, VA / ACCESSWIRE / August 6, 2020 / Adial Pharmaceuticals, Inc.

Developments to be Shared by Dr.

EMA Agreement paves the way for a marketing authorization in Europe after Phase 3CHARLOTTESVILLE, VA / ACCESSWIRE / July 22, 2020 / Adial Pharmaceuticals, Inc.

CHARLOTTESVILLE, VA / ACCESSWIRE / July 6, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL:ADILW) ("Adial"), a clinical-stage biopharmaceutical company focused on the development of treatments for add

CHARLOTTESVILLE, VA / ACCESSWIRE / June 25, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ("Adial"), a clinical-stage biopharmaceutical company focused on the development of treatments for a

CHARLOTTESVILLE, VA / ACCESSWIRE / June 17, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ("Adial"), a clinical-stage biopharmaceutical company focused on the development of treatments for a

CHARLOTTESVILLE, VA / ACCESSWIRE / June 15, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ("Adial" or the "Company"), a biopharmaceutical company focused on the development of treatments for

CHARLOTTESVILLE, VA / ACCESSWIRE / June 11, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ("Adial"), a clinical-stage biopharmaceutical company focused on the development of treatments for a

CHARLOTTESVILLE, VA / ACCESSWIRE / June 10, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ("Adial"), a clinical-stage biopharmaceutical company focused on the development of treatments for a